

July 2021 updates to prior authorizations and post service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on certain medications in order to ensure coverage and payment for those services. A number of requirements have been added for 2021 as we work to make sure all care, services and treatments are medically necessary.

Magellan will implement additional PAs & PSCEs July 1, 2021, which include:

Specialty Drugs in the office-based and outpatient settings

- *Evkeeza[®] (evinacumab-dgnb)*
- *Cosela[®] (TRILACICLIB)*
- *Scenesse[®] (afamelanotide)*
- *Pepaxto[®] (MELPHALAN FLUFENAMIDE)*
- *Supprelin[®] (histrelin acetate) - PSCE Only*
- *Vyondys-53[®] (golodirsen)*
- *Amondys[®] (CASIMERSEN)*

Security Health Plan will implement additional PAs & PSCEs July 1, 2021, which include:

- *Breyanzi[®] (lisocabtagene maraleucl)*
- *Abecma[®] (Idecabtagene Vicleucl)*

This is only the list of new prior authorizations and post service claim edits required of members and providers to ensure payment for services. You can review the full list of medications that will require a prior authorization and/or post service claim edit on our website at

www.securityhealth.org/providers/medical-pharmacy. If you have any questions, please contact Security Health Plan Provider Relations at **1-800-548-1224 (TTY 711)**.